J Korean Med Assoc.  2004 Feb;47(2):119-126. 10.5124/jkma.2004.47.2.119.

Nuclear Medicine Techniques

• Lee KH

• KMID: 1936465
• DOI: http://doi.org/10.5124/jkma.2004.47.2.119

Abstract

Molecular imaging is emerging as an exciting new discipline that deals with imaging of disease on a cellular or genetic level. Nuclear medicine has tra6 tionally focused on noninvasive imaging of in vivo physiology using radiolabeled tracers. As such, molecular imaging has its roots in nuclear medicine and in many ways is a direct extension of this field. The myriad of biological processes that may be targeted for molecular nuclear imaging can be grouped into direct and indirect strategies, depending on the type of imaging probe. The direct strategy uses de novo synthesis of molecular probes targeted to a specific molecular marker such as a receptor, transporter, or enzyme. For each novel target, new radiolabeled compounds are required as well as characterization of their detection sensitivity, interaction specificity, pharmacokinetics of delivery, and signaltonoise ratio. The indirect strategy entails the use of a pretargeting molecule that is subsequently activated upon occurrence of a specific molecular event, which in turn is targeted by a specific molecular radioprobe. Reporter gene imaging falls into this category and provides a rapid and convenient tool to monitor gene expression by yielding a phenotype that is readily imaged upon expression. The remarkable efforts currently focused on the molecular nuclear technology signify its importance and wide range of application. With continued improvements in instrumentation, identification of novel targets, and design of better radioprobes, molecular nuclear imaging promises to play an increasingly important role in disease diagnosis and therapy.

Keyword

Molecular imaging; Nuclear medicine; Radiotracer; Reporter gene

MeSH Terms

Biological Processes
Diagnosis
Gene Expression
Genes, Reporter
Molecular Imaging
Molecular Probes
Nuclear Medicine*
Pharmacokinetics
Phenotype
Physiology
Sensitivity and Specificity
Molecular Probes

Figure

• 

  Figure 1

• 

  Figure 2

Reference

1. Herschman HR. Molecular imaging:Looking at problems, seeing solutions. Science. 2003. 302:605–608.

2. Britz-Cunningham SH, Adelstein SJ. Molecular targeting with radionuclides: State of the science. J Nucl Med. 2003. 44:1945–1961.

3. Weissleder R, Mahmood U. Molecular imaging. Radiology. 2001. 219:3160–3333.

4. Nichol C, Kim EE. Molecular imaging and gene therapy. J Nucl Med. 2001. 42:1368–1374.

5. Gambhir SS, Barrio JR, Herschman HR, Phelps ME. Imaging gene expression: principles and assays. J Nucl Cardiol. 1999. 6(2):219–233.

6. Tjuvajev JG, Chen SH, Joshi A, Joshi R, Guo ZS, Blasberg RG, et al. Imaging adenoviral-mediated herpes virus thymidine kinase gene transfer and expression in vivo. Cancer Res. 1999. 59(20):5186–5193.

7. Gambhir SS, Barrio JR, Phelps ME, Iyer M, Namavari M, Herschman HR, et al. Imaging adenoviral-directed reporter gene expression in living animals with positron emission tomography. Proc Natl Acad Sci USA. 1999. 96(5):2333–2338.

8. Lee KH, Byun SS, Choi JH, Paik JY, Choe YS, Kim BT. Radioiodine labeled phenylethyl-D-thiogalactopyranoside as a radioprobe to monitor lacZ reporter gene expression. Eur J Nucl Med Mol Imaging. 2004. In press.

9. MacLaren DC, Gambhir SS, Satyamurthy N, Barrio JR, Sharfstein S, Herschman HR, et al. Repetitive, non-invasive imaging of the dopamine D2 receptor as a reporter gene in living animals. Gene Ther. 1999. 6(5):785–791.

10. Umegaki H, Ishiwata K, Ogawa O, Ingram DK, Roth GS, Senda M, et al. In vivo assessment of adenoviral vector-mediated gene expression of dopamine D(2) receptors in the rat striatum by positron emission tomography. Synapse. 2002. 43(3):195–200.

11. Doubrovin M, Ponomarev V, Beresten T, Balatoni J, Bornmann W, Gelovani Tjuvajev J, et al. Imaging transcriptional regulation of p53-dependent genes with positron emission tomography in vivo. Proc Natl Acad Sci USA. 2001. 98(16):9300–9305.

12. Costouros NG, Diehn FE, Libutti SK. Molecular imaging of tumor angiogenesis. J Cell Biochem. 2002. 39:Suppl. 72–78.

13. Janssen ML, Oyen WJ, Dijkgraaf I, Massuger LF, Frielink C, Boerman OC, et al. Tumor targeting with radiolabeled αvβ3 integrin binding peptides in a nude mouse model. Cancer Res. 2002. 62:6146–6151.

14. Haubner R, Wester HJ, Weber WA, Mang C, Ziegler SI, Schwaiger M, et al. Noninvasive imaging of αvβ3 integrin expression using ¹⁸F-labeled RGD containing glycopeptide and positron emission tomography. Cancer Res. 2001. 61:1781–1785.

15. Lee KH, Song SH, Paik JY, Byun SS, Lee SY, Choe YS, Kim BT. Specific Endothelial binding and tumor uptake of radiolabeled angiostatin. Eur J Nucl Med Mol Imaging. 2003. 30:1032–1037.

16. Blankenberg F, Ohtsuki K, Wtrauss HW. Dying a thousand deaths: Radionuclide imaging of apoptosis. Q J Nucl Med. 1999. 43:170–176.

17. Blankenberg F, Katsikis PF, Tait JF. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc Natl Acad Sci USA. 1998. 95:6349–6344.